Abattis Bioceuticals Corp Stock Buy Hold or Sell Recommendation
| ATTBF Stock | USD 0.0001 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Abattis Bioceuticals Corp is 'Strong Sell'. Macroaxis provides Abattis Bioceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ATTBF positions.
Check out Abattis Bioceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Abattis and provide practical buy, sell, or hold advice based on investors' constraints. Abattis Bioceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Abattis |
Execute Abattis Bioceuticals Buy or Sell Advice
The Abattis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Abattis Bioceuticals Corp. Macroaxis does not own or have any residual interests in Abattis Bioceuticals Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Abattis Bioceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Abattis Bioceuticals Trading Alerts and Improvement Suggestions
| Abattis Bioceuticals generated a negative expected return over the last 90 days | |
| Abattis Bioceuticals has some characteristics of a very speculative penny stock | |
| Abattis Bioceuticals Corp has accumulated 150.86 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Abattis Bioceuticals Corp has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Abattis Bioceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Abattis Bioceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abattis Bioceuticals Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abattis to invest in growth at high rates of return. When we think about Abattis Bioceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 356.88 K. Net Loss for the year was (3.04 M) with profit before overhead, payroll, taxes, and interest of 241.34 K. |
Abattis Bioceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Abattis Bioceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Abattis Bioceuticals' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Abattis pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Abattis Bioceuticals Volatility Alert
At this time Abattis Bioceuticals Corp exhibits very low volatility. Abattis Bioceuticals Corp appears to be a penny stock. Although Abattis Bioceuticals Corp may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Abattis Bioceuticals Corp or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Abattis instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Abattis Bioceuticals Fundamentals Vs Peers
Comparing Abattis Bioceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Abattis Bioceuticals' direct or indirect competition across all of the common fundamentals between Abattis Bioceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Abattis Bioceuticals or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Abattis Bioceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Abattis Bioceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Abattis Bioceuticals to competition |
| Fundamentals | Abattis Bioceuticals | Peer Average |
| Return On Equity | -0.28 | -0.31 |
| Return On Asset | -0.16 | -0.14 |
| Operating Margin | (10.96) % | (5.51) % |
| Current Valuation | 4.08 M | 16.62 B |
| Shares Outstanding | 477.8 M | 571.82 M |
| Shares Owned By Institutions | 0.02 % | 39.21 % |
| Price To Earning | (5.83) X | 28.72 X |
| Price To Book | 0.38 X | 9.51 X |
| Price To Sales | 1.33 X | 11.42 X |
| Revenue | 356.88 K | 9.43 B |
| Gross Profit | 241.34 K | 27.38 B |
| EBITDA | (2.9 M) | 3.9 B |
| Net Income | (3.04 M) | 570.98 M |
| Cash And Equivalents | 2.4 M | 2.7 B |
| Total Debt | 150.86 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 0.73 X | 2.16 X |
| Book Value Per Share | 0.02 X | 1.93 K |
| Cash Flow From Operations | 9.41 M | 971.22 M |
| Earnings Per Share | (0.01) X | 3.12 X |
| Number Of Employees | 32 | 18.84 K |
| Beta | -60.6 | -0.15 |
| Market Capitalization | 473.03 K | 19.03 B |
| Total Asset | 19.26 M | 29.47 B |
| Retained Earnings | (10.13 M) | 9.33 B |
| Working Capital | (588 K) | 1.48 B |
| Current Asset | 260 K | 9.34 B |
| Current Liabilities | 848 K | 7.9 B |
| Z Score | 1.8 | 8.72 |
| Net Asset | 19.26 M |
Abattis Bioceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Abattis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Abattis Bioceuticals Buy or Sell Advice
When is the right time to buy or sell Abattis Bioceuticals Corp? Buying financial instruments such as Abattis Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Abattis Bioceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Theme ETFs Thematic Idea Now
Theme ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Abattis Pink Sheet
Abattis Bioceuticals financial ratios help investors to determine whether Abattis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abattis with respect to the benefits of owning Abattis Bioceuticals security.